Clinical trials: Liver Transplant Rejection
Graft Rejection, Heart Transplantation
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
The a series of clinical studies of [18F]FSPG PET/CT showed that [18F]FSPG is safe and promising PET tracer for detecting inflammation with favorable biodistribution and pharmacokinetics in patients.
- Conditions
- Graft Rejection, Heart Transplantation, Liver Transplantation
- Trial name
- NCT04488094
- Testing
- [18F]FSPG
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Asan Medical Center
Liver Transplantation (LT), Immuno-suppression
Immune Biomarkers for Predicting Complications After Liver Transplantation
This multicenter prospective observational study will evaluate immune biomarkers in adults undergoing liver transplantation. The study aims to describe how immune markers change before and after transplantation and to assess…
- Conditions
- Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection
- Trial name
- NCT07875595
- Testing
- Immune Biomarker Assessment
- Where
- 3 sites in Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires
Liver Disease, Liver Transplantation
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected.
- Trial name
- TILT (NCT00105235)
- Testing
- Alemtuzumab, Cyclosporine, Mycophenolate mofetil
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant Rejection
Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration
This is a randomized controlled trial in which the safety and feasibility of cell therapy medicinal product shall be measured by comparing the variables of the response after treatment compared to baseline prior to…
- Trial name
- NCT01745731
- Testing
- Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Liver transplantation is a lifesaving procedure; however, there are chances that the body may reject the organ following liver transplantation, and this remains a significant concern.
- Trial name
- NCT06153641
- Testing
- N/A-Observational Study
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Liver Transplant Rejection
MSC Therapy in Liver Transplantation
The general aim of the present study is to test a cell therapy with third-party allogeneic ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients.
- Trial name
- NCT02260375
- Testing
- Mesenchymal Stromal Cells
- Where
- 6 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Monia Lorini
Acute Cellular Graft Rejection, Liver Transplant Rejection
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Our hypothesis is that budesonide will provide effective hepatic ISP that will replace prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and calcineurin-associated complications often observed in…
- Trial name
- BILT (NCT03315052)
- Testing
- Budesonide, Tacrolimus（FK506）, Mycophenolate Mofetil
- Sponsor
- Montefiore Medical Center
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant Rejection
Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation
Liver is an organ that is well-known for its immune tolerant capacity. However, there were still controversial issues about the impact of immunologic challenge after liver transplantation on the graft function.
- Trial name
- NCT01444079
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Immunosuppression
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease…
- Trial name
- NCT07206277
- Testing
- Immunosuppression reduction
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
End Stage Liver Disease, Rejection
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
To search for suitable pharmacodynamic biomarkers, i.e., with high specificity for calcineurin inhibition and most affected by inter-individual variability, our works aimed at exploring the pharmacodynamics of CNI, the strength…
- Conditions
- End Stage Liver Disease, Rejection, Infection, Malignancy
- Trial name
- 3PIGREF (NCT01760356)
- Where
- Uruguay
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- UDA Centro Nacional Hepato-Bilio-Pancreático
Rejection Acute Hepatic, Transplant; Failure, Liver
Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR).
- Conditions
- Rejection Acute Hepatic, Transplant; Failure, Liver, Liver Dysfunction
- Trial name
- ElastOLT (NCT05793203)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Graft Vs Host Disease
Evaluation of the Impact of Reduced Immunosuppression
Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.
- Trial name
- NCT05238155
- Testing
- antimetabolite
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Evidence of Liver Transplantation
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
The prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents.
- Trial name
- MMF-FK (NCT00151632)
- Testing
- Mycophenolate mofetil, Tacrolimus
- Where
- 8 sites in France
- Volunteers
- 195 people
- Sponsor
- Rennes University Hospital
Evidence of Liver Transplantation
Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance
Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. Despite the ability of current immunosuppressive agents to reduce the incidence of acute rejection, the rate of acute rejection…
- Trial name
- NCT01690247
- Testing
- Conventional plus UC-MSC
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Liver Disease
Randomized Controlled Trial of ImmuKnow in Liver Transplantation
ImmuKnow detects cell-mediated immunity in solid-organ transplant recipients undergoing immunosuppressive therapy. Increasing ImmuKnow values indicate a decrease of immunosuppression and decreasing ImmuKnow values suggest an…
- Trial name
- NCT01764581
- Testing
- Tacrolimus regulation according to ImmuKnow values
- Volunteers
- 206 people
- Sponsor
- University of Bologna
Liver Transplant, Liver Transplantation
Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- WISP-R (NCT00320606)
- Testing
- Immunosuppression Withdrawal
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
The aim of the study is to assess whether patients with recurrent hepatitis C after liver transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment for 48 weeks.
- Trial name
- NCT00466219
- Testing
- Ribavirin, Pegylated interferon alpha2a
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Chronic Rejection of Liver Transplant
Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for…
- Trial name
- Treg (NCT01624077)
- Testing
- Regulatory T cells
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Liver Transplant Recipients, Liver Transplantation
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.
- Conditions
- Liver Transplant Recipients, Liver Transplantation, Immunosuppression
- Trial name
- iWITH (NCT01638559)
- Testing
- Immunosuppression withdrawal
- Where
- 12 sites in United States, Canada
- Volunteers
- 161 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)